Agenus Inc. has reported published Phase 1b data for botensilimab plus balstilimab in treatment-refractory hepatocellular carcinoma, showing durable responses and manageable safety in patients who had already progressed after prior immunotherapy. The data, published in Liver Cancer, place the Fc-enhanced anti-CTLA-4 and anti-PD-1 combination into one of the more difficult corners of liver cancer drug development, where patients often have limited systemic treatment options and compromised liver function.
Why Agenus’ HCC data matter in a post-immunotherapy treatment setting with limited options
The most important point in the Agenus data is not simply that botensilimab plus balstilimab produced responses. It is that the combination generated activity in a post-immunotherapy hepatocellular carcinoma population, a setting where clinical evidence remains thin and therapeutic confidence is often limited. Advanced hepatocellular carcinoma has already moved into the checkpoint inhibitor era in frontline treatment, but the treatment sequence after progression remains unsettled. That creates a meaningful opening for therapies that can show activity after prior anti-PD-1 or anti-PD-L1 exposure.
Agenus reported that all patients in the cohort had received prior anti-PD-(L)1 therapy, while 68% had previously received tyrosine kinase inhibitors and 58% had received atezolizumab plus bevacizumab. That matters because this was not an immunotherapy-naïve group where checkpoint sensitivity might be easier to demonstrate. The data instead speak to a harder biological question: whether a next-generation CTLA-4 approach can re-engage immune activity after prior checkpoint exposure.
The limitation is equally clear. The cohort included only 19 treated patients, with 18 considered efficacy evaluable. That makes the signal interesting rather than definitive. In oncology development, small expansion cohorts can identify promising biology, but they cannot settle how a regimen will perform against real-world treatment sequencing, patient heterogeneity, regional practice differences, or larger safety datasets. For Agenus, the next challenge is not proving that the regimen can produce responses. It is proving that the response pattern is reproducible enough to support a clearer development path.
How botensilimab plus balstilimab compares with existing late-line HCC therapies
Agenus reported an objective response rate of 17%, including one complete response and two partial responses, alongside an 18-week clinical benefit rate of 50%. Median progression-free survival was 4.4 months, while median overall survival reached 12.3 months. In isolation, those figures may look modest to a non-specialist reader. In post-immunotherapy hepatocellular carcinoma, however, modest-looking numbers can still be clinically meaningful because the benchmark is low and the patient population is difficult.
The company positioned the results against published experience with late-line systemic therapies such as lenvatinib, cabozantinib and regorafenib after immune checkpoint inhibitor-based treatment, where objective response rates have generally been in the 6% to 14% range, progression-free survival has been roughly four to five months, and median overall survival has often been at or below 10.5 months. That makes the 12.3-month median overall survival figure worth watching, especially because nearly half the cohort had ALBI grade 2 liver function, a marker associated with poorer liver reserve and worse prognosis.
Still, cross-study comparison is the dangerous sport of biotech analysis, and nobody gets a medal for pretending otherwise. Differences in patient selection, prior therapies, liver function, follow-up duration, radiographic assessment, geographic mix and trial design can make apparently favourable comparisons less clean than they look. The Agenus data are encouraging because they are prospective and because the population included adverse prognostic features. They remain early because the sample size is small and because the study was not designed as a randomized comparison against standard late-line options.
What the data reveal about the clinical logic behind Fc-enhanced CTLA-4 therapy
The strategic rationale behind botensilimab is that not all CTLA-4 antibodies are designed to behave the same way. Agenus describes botensilimab as a human Fc-enhanced multifunctional anti-CTLA-4 antibody intended to activate both innate and adaptive immune responses. The therapeutic idea is that stronger immune priming, regulatory T-cell modulation, myeloid cell activation and memory response generation could extend immunotherapy activity into tumors that are cold, resistant or poorly responsive to conventional checkpoint blockade.
That logic is relevant in hepatocellular carcinoma because the disease is shaped by both tumor biology and liver function. Treatment outcomes are not driven only by cancer burden. They are also affected by cirrhosis, inflammation, hepatic reserve and the patient’s ability to tolerate immune-mediated toxicity. A treatment that can trigger durable disease control without unacceptable liver toxicity would therefore have significance beyond response rate alone.
The unresolved issue is whether the mechanism can be separated from toxicity at scale. CTLA-4 biology has always carried a balance-of-risk problem because immune activation can bring immune-mediated adverse events. Agenus reported no treatment-related deaths, no new class safety signals, no grade 4 or higher immune-mediated treatment-related adverse events, and resolution of immune-mediated hepatitis events to grade 1 or lower. However, immune-mediated treatment-related adverse events occurred in 68% of patients, with grade 3 events in 37%. For clinicians, that safety profile may be manageable in expert oncology settings, but broader adoption would depend on predictable monitoring, early intervention, liver-specific risk management and confidence that benefit justifies toxicity in compromised patients.
Why durability may matter more than response rate in refractory liver cancer
One of the more interesting parts of the Agenus dataset is the emphasis on durability and disease control. Median duration of response was not reached, and one patient maintained stable disease for 66 weeks. That suggests the clinical value of botensilimab plus balstilimab may not be captured only by objective response rate. In late-line hepatocellular carcinoma, prolonged stabilization can matter because patients may have few remaining treatment options and because rapid progression often limits later therapeutic choices.
Durability is especially important in immuno-oncology because immune-mediated responses can behave differently from cytotoxic or targeted therapy responses. A small number of deep or long-lasting responses can support further development if the biology appears consistent and if the safety profile is manageable. For Agenus, the presence of a complete response, partial responses and prolonged stable disease creates a signal that is more nuanced than a simple response-rate headline.
The risk is that durability signals from small cohorts can be distorted by individual outliers. A single long responder can meaningfully influence interpretation when the denominator is 18 efficacy-evaluable patients. That does not invalidate the finding, but it does set the bar for future trials. Larger cohorts will need to show whether durable benefit is a repeatable pattern across patient subgroups or a promising but narrow phenomenon.
What regulators and clinicians may need to see before BOT plus BAL advances in HCC
The next clinical question is whether Agenus can define the most rational development route for botensilimab plus balstilimab in hepatocellular carcinoma. A Phase 1b expansion cohort can support biological confidence, but regulatory and clinical adoption pathways usually require stronger evidence, particularly in a competitive oncology field where survival, tolerability and sequencing matter. The clearest value proposition would require larger data in a defined post-ICI population, preferably with stratification by liver function, prior therapy, etiology and biomarker status.
Clinicians will likely watch whether the regimen performs consistently in patients with impaired liver reserve, since ALBI grade 2 representation is one of the more clinically relevant features of this dataset. They will also watch whether immune-mediated hepatitis remains manageable in a larger liver cancer population. Safety events that are acceptable in a tightly monitored early trial can become more complicated in broader practice, especially where patients have underlying cirrhosis or borderline hepatic function.
Regulators will likely focus on the strength of response durability, overall survival interpretation, safety management and whether the treatment addresses a clearly defined unmet need after checkpoint inhibitor progression. If Agenus pursues a larger HCC program, trial design will matter. A single-arm study may be harder to interpret in a treatment landscape with multiple sequencing options, while a randomized design would be more expensive and slower but more persuasive.
What this means for Agenus’ broader immuno-oncology platform
For Agenus, the HCC publication adds another data point to the broader botensilimab and balstilimab story. The combination has already been positioned across difficult-to-treat solid tumors, with the global Phase 3 BATTMAN trial evaluating botensilimab plus balstilimab in refractory microsatellite-stable and mismatch repair-proficient metastatic colorectal cancer. The liver cancer data therefore support the platform narrative that Fc-enhanced CTLA-4 biology may have activity beyond one tumor type.
That platform angle matters commercially because Agenus is not only trying to prove one regimen in one cancer. It is trying to establish a broader immuno-oncology thesis at a time when investors, clinicians and partners have become more selective about checkpoint innovation. The first wave of checkpoint inhibitors transformed oncology, but later combinations have often struggled to balance incremental efficacy with toxicity and development cost. Botensilimab’s opportunity is to show that engineering a differentiated CTLA-4 antibody can produce clinically meaningful activity where older checkpoint approaches have limited effect.
The risk is that platform stories can run ahead of confirmatory evidence. HCC is biologically distinct from colorectal cancer, and success in one setting does not guarantee success in another. The publication strengthens the rationale for further study, but it does not remove the execution burden. Agenus still needs larger, cleaner and more comparative datasets to persuade clinicians and regulators that botensilimab plus balstilimab can become more than an intriguing late-line signal.
The neutral read on Agenus’ post-immunotherapy liver cancer opportunity
A neutral reading suggests Agenus has produced a credible early signal in a difficult hepatocellular carcinoma setting, especially given prior immunotherapy exposure, poor prognostic features and the reported 12.3-month median overall survival. The data are not practice-changing on their own, but they are strong enough to keep botensilimab plus balstilimab in the conversation for post-ICI liver cancer development.
The clinical upside lies in the combination’s potential to deliver durable immune activity after conventional checkpoint therapy has failed. The clinical risk lies in proving that this activity is reproducible and that immune-mediated toxicity remains manageable in larger HCC populations. The commercial upside depends on whether Agenus can carve out a clear treatment niche in a sequencing environment that remains fragmented and evidence-poor.
For now, the publication gives Agenus a stronger footing in the post-immunotherapy HCC debate. The next test is whether the U.S.-based immuno-oncology developer can convert a small but meaningful Phase 1b signal into a development path that clinicians, regulators and potential partners can treat as more than another promising early oncology readout.
